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with BCP double mutations were significantly lower than in 
individuals with the wild-type BCP. However, the difference 
in the concentrations of serum DLD between individuals 
with wild-type BCP and those negative for HBsAg was not 
significant.  Conclusions: HBV with BCP double mutations 
are associated with lower concentrations of serum DLD. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Hepatocellular carcinoma (HCC) is the most common 
primary malignancy of the liver. Globally, it is the fifth 
most common cancer in men, and seventh among wom-
en, with over half a million new cases diagnosed annually 
worldwide  [1] . The great majority of liver cancer (>80%) 
occurs in either sub-Saharan Africa or in Eastern Asia, 
with one country alone, China, accounting for over 50% 
of cases  [2] . When specific diagnostic tests for hepatitis B 
virus (HBV) infection were introduced in the early 1970s, 
it became clear that there is a strong etiological associa-
tion between chronic HBV infection and the develop-
ment of HCC  [3] . However, the mechanisms of oncogen-
esis remain obscure.
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 Abstract 
 Objectives: The aim of this study was to identify serum pro-
teins with differential concentrations between hepatocellu-
lar carcinoma (HCC) patients and HBsAg asymptomatic car-
riers among individuals infected with hepatitis B virus (HBV) 
with basal core promoter (BCP) double mutations (A1762T, 
G1764A).  Methods: iTRAQ and liquid chromatography-tan-
dem mass spectrometry were used to identify differentially 
expressed protein, and an ELISA test was used for the valida-
tion test.  Results: The total number of proteins identified 
was 1,125, of which 239 showed statistically significant dif-
ferences in their expression. The relative concentrations of 
serum dihydrolipoyl dehydrogenase (DLD), which showed 
the most significant correlation with liver diseases and infec-
tion, were significantly lower in HCC patients than asymp-
tomatic HBsAg carriers and individuals negative for HBsAg. 
However, only the difference between HCC patients with 
BCP double mutations and HBsAg-negative individuals 
could be confirmed by ELISA. Meanwhile, we found that the 
concentrations of serum DLD in those infected with HBV 
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 HBV has a circular, partially double-stranded DNA 
genome of about 3,200 nt with four open reading frames 
(ORFs), namely the core/precore, polymerase, surface 
and X ORFs  [4] . Transcription of the four ORFs is con-
trolled by the core, large surface, major surface and X pro-
moters. The core promoter, located between nt 1,575 and 
1,849, consists of the basal core promoter (BCP; nt 1,743–
1,849) and the upper regulatory region (nt 1,613–1,742) 
 [5] . The genome replicates via an RNA intermediate and 
the lack of proofreading during reverse transcription of 
the pregenomic RNA favors the development of sequence 
variants during long-term HBV replication  [6] . One of 
the most critical changes is the appearance of double mu-
tations at nt 1,762 (A-T) and 1,764 (G-A) in the BCP  [7] . 
This has been reported to be associated with the patho-
genesis of progressive liver disease, including HCC  [8–
11] .
 In our initial studies  [9, 10] , we found BCP double mu-
tations in HBV from 96% of HCC patients, but only 24% 
of controls, from Guangxi, China. In order to determine 
the value of screening HBsAg carriers for virus with BCP 
double mutations as a marker of extremely high risk of 
developing HCC, we are carrying out a prospective co-
hort study in Long An county, southern Guangxi. Within 
this cohort, we found that 93.3% of the male HCC cases 
were infected with the mutant  [12] . Clearly, the double 
mutations are an etiological factor of HCC. The preva-
lence of BCP double mutations in the population where 
the cohort was established is 53%. It is also clear that not 
all of those infected by HBV with BCP double mutations 
ultimately develop HCC. What is the difference between 
those who will develop HCC and those who will not, 
among individuals infected with HBV with BCP double 
mutations? The answer will enable us to understand fur-
ther the mechanisms of oncogenesis of HBV and, prob-
ably, obtain a good biomarker for HCC.
 The aim of this study was to identify serum proteins 
with differential concentrations among HCC patients in-
fected with HBV with BCP double mutations, asymptom-
atic HBsAg carriers with BCP double mutations and in-
dividuals negative for HBsAg, using iTRAQ (isobaric tags 
for relative and absolute quantification)  [13] and liquid 
chromatography-tandem mass spectrometry.
 Materials and Methods 
 Serum Sample Collection 
 Serum samples were collected from patients from Guangxi 
Medical University and the Long An cohort  [12] . The patients who 
provided serum samples for proteomic analysis and for the valida-
tion of the significantly differentially expressed protein included 
HCC cases, asymptomatic HBsAg carriers and HBsAg-negative 
individuals. All blood samples were incubated at room tempera-
ture for 30 min and centrifuged for 10 min at 3,000 rpm (1,600  g ). 
The serum samples were divided into three aliquots and processed 
independently as biological triplicates to assess the reproducibility 
of the data. The sera were stored at  − 80  °  C until the analysis.
 Informed consent in writing was obtained from each individu-
al. The study protocol conformed to the ethical guidelines of the 
1975 Declaration of Helsinki and was approved by the Guangxi 
Institutional Review Board.
 Serological Testing and HBV DNA Amplification and 
Sequencing 
 The tests for HBsAg, HBeAg/anti-HBe and alanine amino-
transferase (ALT) in serum, and amplification of the BCP of HBV 
DNA and nucleotide sequencing were as described previously 
 [12] .
 Protein Preparation 
 To reduce the complexity of the samples, highly abundant pro-
teins were depleted using ProteoMiner TM kits (Bio-Rad Laborato-
ries, Hercules, Calif., USA) according to the manufacturer’s pro-
tocol. Briefly, the samples were eluted in Lysis buffer (7  M urea, 2 
 M thiourea, 4% CHAPS, 40 m M Tris-HCl, pH 8.5) and reduced 
with 10 m M DTT (final concentration) at 56   °   C for 1 h, followed 
by alkylation with 55 m M IAM (final concentration) for 1 h in the 
dark. The reduced and alkylated protein mixtures were precipi-
tated by adding 4× volume of chilled acetone at –20  °  C overnight. 
After centrifugation at 4  °  C, 30,000  g , the pellet was dissolved in 0.5 
 M TEAB (Applied Biosystems, Milan, Italy) and sonicated on ice. 
After centrifuging at 30,000  g at 4  °  C, an aliquot of the supernatant 
was taken for the determination of protein concentration using the 
Bradford method with BSA as a standard  [14] . The proteins in the 
supernatants were kept at –80  °  C for further analysis.
 iTRAQ Labeling and SCX Fractionation 
 Total protein (100 μg) was taken from each sample solution and 
digested with Trypsin Gold (Promega, Madison, Wis., USA), with 
a ratio of protein:trypsin of 30: 1, for 16 h at 37   °   C. After trypsin 
digestion, the peptides were dried by vacuum centrifugation. The 
peptides were reconstituted in 0.5  M TEAB and processed accord-
ing to the manufacturer’s protocol for the 8-plex iTRAQ reagent 
(Applied Biosystems). Briefly, 1 unit of iTRAQ reagent was thawed 
and reconstituted in 24 μl of isopropanol. Peptides were labeled 
with 116, 118 and 121 iTRAQ tags by incubation at room temper-
ature for 2 h. The labeled peptide mixtures were then pooled and 
dried by vacuum centrifugation.
 SCX (strong cation exchange) chromatography was performed 
with an LC-20AB HPLC Pump system (Shimadzu, Kyoto, Japan). 
The iTRAQ-labeled peptide mixtures were reconstituted with 4 ml 
of buffer A (25 m M  NaH 2 PO 4 in 25% ACN, pH 2.7) and loaded 
onto 4.6 × 250 mm Ultremex SCX columns containing 5-μm par-
ticles (Phenomenex). The peptides were eluted at a flow rate of 1 
ml/min with a gradient of buffer A for 10 min, 5–60% buffer B (25 
m M NaH 2 PO 4 , 1  M KCl in 25% ACN, pH 2.7) for 27 min, and 60–
100% buffer B for 1 min. The system was then maintained at 100% 
buffer B for 1 min before equilibrating with buffer A for 10 min 
prior to the next injection. Elution was monitored by measuring 
the absorbance at 214 nm and fractions were collected every 1 min. 
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The eluted peptides were pooled into 20 fractions, desalted with a 
Strata X C18 column (Phenomenex) and vacuum dried.
 LC-ESI-MS/MS Analysis Based on Triple TOF 5600 
 LC-ESI-MS/MS (liquid chromatography-electrospray ioniza-
tion tandem mass spectrometry) analysis based on Triple TOF 
(time-of-flight) 5,600 was performed. Each fraction was resus-
pended in buffer A (5% ACN, 0.1% FA) and centrifuged at 20,000 
 g for 10 min; the final concentration of peptide was about 0.5 μg/
μl on average. Ten microliters of supernatant was loaded onto an 
LC-20AD nanoHPLC (Shimadzu, Kyoto, Japan) by the autosam-
pler onto a 2-cm C18 trap column. The peptides were then eluted 
onto a 10-cm analytical C18 column (inner diameter 75 μm) 
packed in-house. The samples were loaded at 8 μl/min for 4 min, 
then the 35-min gradient was run at 300 nl/min starting from 2 to 
35% B (95% ACN, 0.1% FA), followed by a 5-min linear gradient 
to 60%, then a 2-min linear gradient to 80%, maintenance at 80% 
B for 4 min, and finally a return to 5% for 1 min.
 Data acquisition was performed with a Triple TOF 5600 system 
(AB SCIEX, Concord, Ont., Canada) fitted with a Nanospray III 
source (AB SCIEX) and a pulled quartz tip as the emitter (New 
Objectives, Woburn, Mass., USA). Data were acquired using an 
ion spray voltage of 2.5 kV, curtain gas of 30 psi, nebulizer gas of 
15 psi, and an interface heater temperature of 150  °  C. The MS was 
operated with a reverse phase greater than or equal to 30,000 full 
width at half maximum for TOF MS scans. For IDA, survey scans 
were acquired in 250 ms and as many as 30 product ion scans were 
collected if exceeding a threshold of 120 counts/s and with a 2+ to 
5+ charge state. The total cycle time was fixed to 3.3 s. The Q2 
transmission window was 100 Da for 100%. Four time bins were 
summed for each scan at a pulser frequency value of 11 kHz 
through monitoring of the 40-GHz multichannel TDC detector 
with four-anode channel detection. A sweeping collision energy 
setting of 35 ± 5 eV coupled with iTRAQ adjust rolling collision 
energy was applied to all precursor ions for collision-induced dis-
sociation. The dynamic exclusion was set for 1/2 of the peak width 
(15 s) and then the precursor was refreshed off the exclusion list.
 Data Analysis 
 Mass spectra from the 20 fractions were combined into one 
MGF (Mascot generic format) file, and the MGF file was searched 
against the International Protein Index (IPI) human sequence da-
tabases (version 3.87, human, 91,464 sequences) using Mascot 
software (version 2.3.02; Matrix Science, London, UK). The search 
parameters were as follows: the fixed modifications were carbami-
domethyl (C), iTRAQ8plex (N-term) and iTRAQ8plex (K), and 
the variable modifications were Gln → pyro-Glu (N-term Q), oxi-
dation (M) and iTRAQ8plex (Y). The peptide mass tolerance was 
0.05 Da and fragment mass tolerance was 0.1 Da. Trypsin was cho-
sen as the enzyme with one missed cleavage allowed; an automatic 
decoy database search strategy was employed to estimate the FDR 
(false discovery rate). In the final search results, the FDR was <0.05. 
All identified peptides had an ion score above the Mascot peptide 
identity threshold and a protein was considered identified if at least 
one such unique peptide match was apparent for the protein. For 
protein quantitation, the filters were set as follows: ‘median’ was 
chosen for the protein ratio type; the minimum precursor charge 
was set to 2+ and minimum peptide was set to 2; only unique pep-
tides were used to quantify proteins. The median intensities were 
set as normalization and outliers were removed automatically. 
Proteins with a 1.2-fold or more change and p value <0.05 were 
considered as differentially expressed proteins. The logarithm of 
the ratio to base 2 below zero was considered to be downregulated, 
whereas those above zero were considered upregulated. Gene On-
tology (GO) functional classifications were analyzed with Blast-
2GO software (http://www.blast2go.org/) and GO enrichment 
analysis was performed to identify GO terms that were significant-
ly enriched in differentially expressed proteins.
 Validation of the Significantly Differentially Expressed Protein 
Dihydrolipoyl Dehydrogenase by ELISA  
 Dihydrolipoyl dehydrogenase (DLD) in sera was measured
using an ELISA kit for DLD (Shanghai Xin Yu Biotech Co. Ltd, 
Shanghai, China) according to the manufacturer’s instructions. 
The concentration of the protein in each sample was determined 
from a standard curve based on serial dilutions of the protein stan-
dard provided in the kit.
 Statistical Analysis 
 Results for continuous variables with normal distributions are 
given as the mean ± standard deviation (SD). Student’s t test was 
used to compare means between two groups. The results for con-
tinuous variables that were not normally distributed are given as 
the median (range) and were compared using the Mann-Whitney 
U test. Multiple linear regression analyses were performed to iden-
tify independent factors associated with concentrations of proteins 
identified in serum. If necessary, a logarithmic transformation was 
applied to concentrations of identified proteins prior to analysis to 
achieve an approximately normal distribution. All p values were 
two-tailed and p < 0.05 was considered to be significant. All statis-
tical analyses were performed using the SPSS software (version 
16.0; SPSS, Chicago, Ill., USA). 
 Results 
 Demographics of the Subjects 
 The total number of samples for proteomic analysis 
was 30, which consisted of the following: group A, 10 
samples from HCC patients infected with HBV with BCP 
double mutations; group B, 10 samples from asymptom-
atic HBsAg carriers with BCP double mutations, and 
group C, 10 samples from HBsAg-negative individuals 
( table 1 ). The total number of samples for the validation 
of the significantly differentially expressed protein was 
167, including 30 from HCC patients infected with HBV 
with BCP double mutations, 44 from asymptomatic
HBsAg carriers infected with HBV with BCP double mu-
tations, 47 from asymptomatic HBsAg carriers infected 
with HBV with wild-type BCP and 46 HBsAg-negative 
individuals ( table 2 ).
 Identification of Differentially Expressed Proteins 
 The total number of proteins identified by iTRAQ was 
1,125, of which 239 showed statistically significant differ-
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ences in their expression when the relative protein con-
centrations of group A and group B, or group A and 
group C, were compared ( fig. 1 ). The number of upregu-
lated proteins in both group A versus group B and group 
A versus group C was 5, and that of the downregulated 
proteins in both group A versus group B and group A 
versus group C was 3 ( table 3 .).
 Validation of the iTRAQ Ratio by ELISA 
 The protein which showed the most significant corre-
lation with liver diseases and infection was validated by 
ELISA. In this study, DLD was selected for the validation. 
In the results from iTRAQ, the relative concentrations of 
DLD in HCC cases with BCP double mutations, asymp-
tomatic HBsAg carriers with BCP double mutations and 
HBsAg-negative individuals were 10, 12.69 and 14.43, re-
spectively. 
 The concentrations of serum DLD in HCC cases with 
BCP double mutations, asymptomatic HBsAg carriers 
with BCP double mutations and HBsAg-negative indi-
viduals were 117.3 ± 33.8, 109.0 ± 34.5 and 205.1 ± 154.8 
pg/ml, respectively. The difference in the concentrations 
of serum DLD between HCC cases with BCP double mu-
 Table 1.  Demographics of subjects for iTRAQ testing
Group n Male Age, years HBsAg (+) HBeAg (+) Anti-HBe (+) ALT (≥40 IU/ml)
A: HCC-DM 10 10 48.8 ± 8.7 10 3 7 9
B: ASC-DM 10 10 48.5 ± 6.6 10 2 8 7
C: HBsAg (–) 10 10 47.9 ± 9.9 0 0 0 2
Total 30 30 48.4 ± 8.2 20 5 15 18
 ASC = Asymptomatic HBsAg carriers; DM = double mutations.
 Table 2.  Demographics of subjects for validation testing
Group n Male Age, years HBsAg (+) HBeAg (+) ALT (≥40 IU/ml), %
HCC 30 28 52.1 ± 9.4 30 8 66.7 (20/30)
ASC-WT 46 27 50.8 ± 7.6 46 14 15.2 (7/46)
ASC-DM 45 24 43.8 ± 7.5 45 6 37.8 (17/45)
HBsAg (–) 46 34 30.5 ± 10.5 0 0 4.3 (2/46)
Total 167 113 43.6 ± 12.3 121 28 27.5 (46/167)
 ASC = Asymptomatic HBsAg carriers; WT = wild-type; DM = double mutations.
44 3
44 5
Group B vs. group A
73
62
Group C vs. group A
 Fig. 1. The numbers of upregulated ( ↑ ) and downregulated ( ↓ ) pro-
teins. The number of upregulated proteins was 44 + 5 in group A 
versus B and 62 + 5 in group A versus C. The number of down-
regulated proteins was 44 + 3 in group A versus B and 73 + 3 in 
group A versus C. The numbers of upregulated and downregu-
lated proteins in both group A versus group B and group A versus 
group C were 5 and 3, respectively. 
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tations and asymptomatic HBsAg carriers with BCP dou-
ble mutations was not significant (t = 1.235, p = 0.221). 
However, the difference in the concentrations of serum 
DLD between the HBsAg-negative group and asymptom-
atic HBsAg carriers with BCP double mutations or the 
HBsAg-negative group and the HCC cases with BCP dou-
ble mutations was significant (t = 4.105, p = 0.0001 and
t = 3.714, p = 0.001, respectively), suggesting that the
concentrations of serum DLD in those infected with HBV 
are lower.
 In order to determine whether there is any difference 
in the concentrations of serum DLD between HBsAg car-
riers with BCP double mutations and those with the wild-
type BCP, DLD from asymptomatic HBsAg carriers in-
fected with HBV with the wild-type BCP were tested. The 
concentration of serum DLD in asymptomatic HBsAg 
carriers with the wild-type BCP was 167.6 ± 163.6 pg/ml. 
The differences between asymptomatic HBsAg carriers 
infected with HBV with the wild-type BCP and asymp-
tomatic HBsAg carriers with BCP double mutations or 
HCC cases with BCP double mutations were significant 
(t = 2.376, p = 0.021, and t = 2.022, p = 0.048, respec-
tively). However, the concentrations of serum DLD of
asymptomatic carriers with the wild-type BCP were not 
significantly different from those of HBsAg-negative in-
dividuals (t = 1.129, p = 0.262). These results suggest that 
lower concentrations of serum DLD in individuals infect-
ed with HBV are attributable to BCP double mutations.
 Multiple linear regression analysis was carried out to 
identify the factors that affect the concentrations of serum 
DLD. The independent variables included sex, age, BCP 
double mutations and ALT. HBeAg was not included be-
cause its correlation with BCP double mutations is more 
than 0.8. The results showed that ALT and BCP double 
mutations were associated with the concentrations of
serum DLD (t = 2.463, p = 0.015, and t = 2.352, p = 0.020, 
respectively;  table 4 ).
 Discussion 
 The major finding of this study is that HBV with BCP 
double mutations is associated with lower concentrations 
of serum DLD. The initial aim of the study was to iden-
tify serum proteins with differential concentrations be-
tween HCC patients and HBsAg asymptomatic carriers 
among individuals infected with HBV with BCP double 
mutations. We found that the relative concentrations of 
serum DLD differed significantly in the iTRAQ test be-
tween HCC patients and HBsAg asymptomatic carriers, 
and between HCC patients and HBsAg-negative individ-
uals. However, only the difference between HCC patients 
and HBsAg-negative individuals could be confirmed by 
 Table 3.  Up- and downregulated proteins in both group A versus group B and group A versus group C
Upregulated protein iTRAQ ratio Downregulated protein  iTRAQ ratio
A vs. B A vs. C A v s. B A vs. C
Complement protein C4B
frameshift mutant
(fragment) 3.668 2.783
DLD
Isoform 2 of calcium-binding
mitochondrial carrier protein Aralar2
Isoform 2 of ribosome-releasing
factor 2, mitochondrial
0.788
0.62
0.542
0.693
0.595
0.582
Keratin, type II cytoskeletal 
2 epidermal 2.223 2.067
Hemoglobin subunit beta 1.595 1.331
Isoform M1 of pyruvate
kinase PKM 1.494 1.382
Eosinophil cationic protein 1.518 1.216
 Table 4.  Multiple linear regression analysis for factors associated 
with the development of BCP double mutations
Variable Unstandardized 
 coefficients
Standardized 
coefficients
(beta)
t Signifi-
cance
 B standard 
error
(Constant) 2.057 0.127 16.197 0.000
Sex 0.020 0.041 0.045 0.484 0.629
Age 0.033 0.026 0.114 1.274 0.205
ALT 0.106 0.043 0.243 2.463 0.015
BCP –0.096 0.041 –0.223 –2.352 0.020
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ELISA. Meanwhile, we found that the concentrations of 
serum DLD in those infected with HBV with BCP double 
mutations is significantly lower than individuals with the 
wild-type BCP. However, the difference was not seen be-
tween individuals with the wild-type BCP and those neg-
ative for HBsAg. Clearly, HBV with BCP double muta-
tions are associated with lower concentrations of serum 
DLD.
 There have been some studies aiming to identify se-
rum biomarkers of HCC for early diagnosis using iTRAQ. 
These have compared proteins differentially expressed in 
serum between HCC and chronic hepatitis B patients  [15, 
16] . In this study, we selected controls from those infect-
ed with HBV with BCP double mutations, representing 
individuals who have been confirmed to be at highest risk 
for the development of HCC  [12] .
 DLD is the common flavoprotein component of the 
three mammalian α-keto acid dehydrogenase complexes, 
namely the pyruvate dehydrogenase complex, the α-ke-
toglutarate dehydrogenase complex and the branched-
chain α-keto acid dehydrogenase complex. The DLD 
component is also present in the glycine cleavage system 
 [17] . DLD has multiple roles in the energy metabolism 
and redox balance and is present in at least four multi-
enzyme complexes  [18] . A deficiency of DLD may lead to 
a range of presentations, mostly characterized by severe 
neurological impairment in early childhood with enceph-
alopathy and seizures  [19, 20] . Liver injury is one of the 
results of DLD deficiency. Affected individuals frequent-
ly experience lifelong recurrent attacks of hepatopathy 
 [21] . 
 The association of viral infection with autoantibodies 
has been strongly suggested. Epstein-Barr virus, hepatitis 
B and C viruses, human immunodeficiency virus and hu-
man parvovirus B19 appear to be associated with auto-
antibodies more frequently than other viruses. Several 
studies have suggested that chronic HBV or HCV may
act as a trigger factor for the development of autoimmune 
rheumatic diseases  [22] . Autoantibodies are common in 
chronic HBV infection  [23, 24] . Autoantibody formation 
may occur in children with chronic HBV infection  [25] . 
DLD has been found to be a major autoantigen in hepa-
titis C virus infection  [26] and a target of autoantibodies 
in endometrial cancer  [27] .
 BCP double mutations were first described in the core 
promoter of HBV from Japanese patients  [7, 28] . Subse-
quently, we and others found that the double mutations 
are associated with more severe liver diseases, including 
HCC  [8–11] . The association between the double muta-
tions and HCC has been confirmed by prospective studies 
 [12, 29, 30] . However, the mechanisms of oncogenesis of 
BCP double mutations remain obscure.
 The development of BCP double mutations is the re-
sult of immune selection  [31] and the selection consoli-
dates the persistence of HBV infection  [32] . In this study, 
we found that individuals infected with HBV with BCP 
double mutations have lower concentrations of serum 
DLD than those with the wild-type BCP. It may be pos-
tulated that BCP double mutations may induce more au-
toantibody against DLD, resulting in lower concentra-
tions of serum DLD. If so, it is not difficult to understand 
that BCP double mutations are associated with more se-
vere liver diseases because the DLD deficiency may cause 
liver injury  [21] . This may be one of the clues for the study 
of the mechanisms of oncogenesis of BCP double muta-
tions.
 Serum concentrations of ALT have been regarded as 
markers of liver injury, including a wide range of etiolo-
gies from viral hepatitis to fatty liver  [33] . We found that 
the level of ALT is associated with the concentration of 
serum DLD. Sex and age were not found to be associated 
with the concentrations of serum DLD in this study. We 
did not determine the concentrations of DLD in acute 
and chronic hepatitis and liver cirrhosis but are planning 
to answer these questions in the future. Furthermore, a 
comparison of the concentrations of autoantibody against 
DLD between those infected with HBV with BCP double 
mutations and those with the wild-type BCP may help 
determine whether the mutations induce more autoanti-
bodies against DLD.
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